Xi-Wen Bi
Overview
Explore the profile of Xi-Wen Bi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
595
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hong R, Xu F, Xia W, Teng Y, Ouyang Q, Zheng Q, et al.
J Clin Oncol
. 2025 Jan;
:JCO2400938.
PMID: 39746176
Purpose: The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial. Methods: Randomized clinical trials were conducted at 12 centers...
2.
Chen Y, Li W, Wu J, Chen G, Yang C, Lu H, et al.
Breast Cancer (Dove Med Press)
. 2024 Apr;
16:223-231.
PMID: 38628818
Purpose: Results from studies of extended capecitabine after the standard adjuvant chemotherapy in early stage triple-negative breast cancer (TNBC) were inconsistent, and only low-dose capecitabine from the SYSUCC-001 trial improved...
3.
Wang L, Jiang C, Wang N, Wen Y, Wang S, Xue C, et al.
BMC Cancer
. 2023 Dec;
23(1):1227.
PMID: 38093246
Background: The association between chemotherapy-induced leukopenia (CIL) and survival for patients with early breast cancer (EBC) is not known. We investigated the relationship between different grades of CIL and survival...
4.
Imoto S, Wang K, Bi X, Liu G, Im Y, Im S, et al.
Breast Cancer
. 2023 Jan;
30(3):412-423.
PMID: 36689066
Background: An international retrospective cohort study was conducted to clarify the survival advantage of combination therapy with locoregional and systemic therapy (ST) in oligometastatic breast cancer (BC). Methods: Patients with...
5.
Wang L, Zhang Y, Jiang C, Duan F, Yuan Z, Huang J, et al.
J Inflamm Res
. 2022 Jul;
15:3957-3974.
PMID: 35860229
Background: The value of the lymphocyte-to-C-reactive protein (CRP) ratio (LCR) in early breast cancer (BC) is unclear. We explored the correlation between the LCR and survival of patients with early...
6.
Hua X, Bi X, Zhao J, Shi Y, Lin Y, Wu Z, et al.
Clin Cancer Res
. 2021 Nov;
28(4):637-645.
PMID: 34810217
Purpose: There is no research evidence demonstrate which is the better partner strategy, endocrine therapy or chemotherapy, to combine with anti-HER2 therapy as the first-line management of hormone receptor (HR)-positive...
7.
Huang Z, Wen W, Hua X, Song C, Bi X, Huang J, et al.
Front Oncol
. 2021 Aug;
11:583283.
PMID: 34336633
Background: A higher ratio of pretreatment C-reactive protein/albumin ratio (CAR) is associated with poor prognosis in nasopharyngeal carcinoma (NPC), and Epstein-Barr virus (EBV) DNA level is known to not only...
8.
9.
Wang X, Wang S, Huang H, Cai L, Zhao L, Peng R, et al.
JAMA
. 2020 Dec;
325(1):50-58.
PMID: 33300950
Importance: Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. Effective strategies to reduce the risk of relapse...
10.
Huang Z, Song C, Huang J, Xia W, Bi X, Hua X, et al.
Gland Surg
. 2020 Nov;
9(5):1370-1379.
PMID: 33224812
Background: Breast cancer is one of the most common malignancy in women with high mortality rate. Given the growing evidence shows that immune-inflammatory system influences the survival of patients with...